RPS6KA1 and acute myeloid leukemia: Thus, the present study suggests that RSK1 may represent a promising molecular target, along with PIM or PI3K, for novel therapeutic strategies against therapy-resistant FLT3-ITD-positive AML with a poor prognosis.